AVITA Medical Free Cash Flow (FCF) History (RCEL)
AVITA Medical reported −$32.2M in free cash flow for fiscal 2025, an increase of $25.9M from the previous fiscal year, with a free cash flow margin of −45.43%.
View full AVITA Medical company overviewAVITA Medical free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$32.2M | $25.9M | — | −45.43% |
| 2024 | 2024-12-31 | −$58.1M | −$18.7M | — | −90.95% |
| 2023 | 2023-12-31 | −$39.4M | −$19.9M | — | −78.56% |
| 2022 | 2022-12-31 | −$19.5M | $7.3M | — | −56.77% |
| 2021 | 2021-06-30 | −$26.8M | −$3.5M | — | −91.66% |
| 2020 | 2020-06-30 | −$23.3M | −$3.1M | — | −163.62% |
| 2019 | 2019-06-30 | −$20.3M | −$6.9M | — | −370.31% |
| 2018 | 2018-06-30 | −$13.3M | — | — | −1434.34% |
AVITA Medical quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$3.6M | $7.1M | — | −16.77% |
| Q1 2026 | 2026-03-31 | −$10.1M | $439,000 | — | −52.93% |
| Q4 2025 | 2025-12-31 | −$6.1M | $3.6M | — | −35.06% |
| Q3 2025 | 2025-09-30 | −$6.2M | $4.8M | — | −36.41% |
| Q2 2025 | 2025-06-30 | −$10.8M | $4.7M | — | −59.00% |
| Q1 2025 | 2025-03-31 | −$10.5M | $11.5M | — | −57.46% |
| Q4 2024 | 2024-12-31 | −$9.7M | $1.5M | — | −53.22% |
| Q3 2024 | 2024-09-30 | −$11.0M | −$1.5M | — | −56.58% |
| Q2 2024 | 2024-06-30 | −$15.4M | −$6.0M | — | −101.64% |
| Q1 2024 | 2024-03-31 | −$22.0M | −$12.7M | — | −198.23% |
| Q4 2023 | 2023-12-31 | −$11.2M | −$7.7M | — | −78.61% |
| Q3 2023 | 2023-09-30 | −$9.5M | −$6.6M | — | −69.45% |
| Q2 2023 | 2023-06-30 | −$9.4M | −$5.7M | — | −79.98% |
| Q1 2023 | 2023-03-31 | −$9.4M | $77,000 | — | −88.69% |
| Q4 2022 | 2022-12-31 | −$3.5M | −$2.9M | — | −37.08% |
| Q3 2022 | 2022-09-30 | −$2.9M | $1.2M | — | −31.69% |
| Q2 2022 | 2022-06-30 | −$3.7M | $5.1M | — | −44.64% |
| Q1 2022 · Mar 31 | 2022-03-31 | −$9.4M | −$3.5M | — | −125.14% |
| Q1 2022 · Sep 30 | 2021-09-30 | −$639,000 | $7.3M | — | −9.10% |
| Q4 2021 | 2021-06-30 | −$4.1M | $2.0M | — | −39.70% |
| Q3 2021 | 2021-03-31 | −$8.9M | −$1.2M | — | −101.16% |
| Q2 2021 | 2020-12-31 | −$5.9M | −$1.2M | — | −116.36% |
| Q1 2021 | 2020-09-30 | −$7.9M | −$3.0M | — | −156.56% |
| Q4 2020 | 2020-06-30 | −$6.0M | — | — | −155.89% |
| Q3 2020 | 2020-03-31 | −$7.6M | — | — | −196.83% |
| Q2 2020 | 2019-12-31 | −$4.7M | — | — | −144.06% |
| Q1 2020 | 2019-09-30 | −$5.0M | — | — | −152.83% |
AVITA Medical free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$23.3M to −$32.2M, a net decrease of $8.9M. AVITA Medical's latest reported quarter, Q2 2026, generated −$3.6M in free cash flow, an increase of $7.1M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review AVITA Medical filings at SEC.gov ↗